FR2717496B1 - Virus recombinants, préparation et utilisation en thérapie génique. - Google Patents

Virus recombinants, préparation et utilisation en thérapie génique.

Info

Publication number
FR2717496B1
FR2717496B1 FR9403191A FR9403191A FR2717496B1 FR 2717496 B1 FR2717496 B1 FR 2717496B1 FR 9403191 A FR9403191 A FR 9403191A FR 9403191 A FR9403191 A FR 9403191A FR 2717496 B1 FR2717496 B1 FR 2717496B1
Authority
FR
France
Prior art keywords
preparation
gene therapy
recombinant viruses
viruses
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9403191A
Other languages
English (en)
French (fr)
Other versions
FR2717496A1 (fr
Inventor
Laurent Pradier
Pascal Barneoud
Pia Delaere
Michel Perricaudet
Emmanuelle Vigne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Aventis Pharma SA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Rhone Poulenc Rorer SA
Institut Gustave Roussy (IGR)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9403191A priority Critical patent/FR2717496B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Rhone Poulenc Rorer SA, Institut Gustave Roussy (IGR) filed Critical Centre National de la Recherche Scientifique CNRS
Priority to MX9603490A priority patent/MX9603490A/es
Priority to AU18962/95A priority patent/AU703793B2/en
Priority to EP95911371A priority patent/EP0750676A1/fr
Priority to KR1019960705207A priority patent/KR970701784A/ko
Priority to CA002184200A priority patent/CA2184200A1/fr
Priority to JP7524417A priority patent/JPH09510358A/ja
Priority to PCT/FR1995/000250 priority patent/WO1995025804A1/fr
Priority to IL11299295A priority patent/IL112992A0/xx
Priority to ZA952244A priority patent/ZA952244B/xx
Publication of FR2717496A1 publication Critical patent/FR2717496A1/fr
Application granted granted Critical
Publication of FR2717496B1 publication Critical patent/FR2717496B1/fr
Priority to NO963559A priority patent/NO963559L/no
Priority to FI963674A priority patent/FI963674A0/fi
Priority to US10/742,920 priority patent/US20040224409A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR9403191A 1992-09-25 1994-03-18 Virus recombinants, préparation et utilisation en thérapie génique. Expired - Fee Related FR2717496B1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR9403191A FR2717496B1 (fr) 1994-03-18 1994-03-18 Virus recombinants, préparation et utilisation en thérapie génique.
JP7524417A JPH09510358A (ja) 1994-03-18 1995-03-02 脳−誘導神経栄養因子（ｂｄｎｆ）をコードする組み換えアデノウィルス
AU18962/95A AU703793B2 (en) 1994-03-18 1995-03-02 Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)
EP95911371A EP0750676A1 (fr) 1994-03-18 1995-03-02 Adenovirus recombinants codant pour le facteur neurotrophique derive du cerveau (bdnf)
KR1019960705207A KR970701784A (ko) 1994-03-18 1995-03-02 뇌-유도 향신경성 인자(BDNF)를 암호화하는 재조합 아데노비루스(Recombinant Adenoviruses Coding for Brain-Derived Neurotrophic Factor(BDNF))
CA002184200A CA2184200A1 (fr) 1994-03-18 1995-03-02 Virus recombinants, preparation et utlisation en therapie genique
MX9603490A MX9603490A (es) 1994-03-18 1995-03-02 Adenovirus recombinantes que codifican para el factor neurotrofico derivado del cerebro (bdnf).
PCT/FR1995/000250 WO1995025804A1 (fr) 1994-03-18 1995-03-02 Adenovirus recombinants codant pour le facteur neurotrophique derive du cerveau (bdnf)
IL11299295A IL112992A0 (en) 1994-03-18 1995-03-14 Recombinant viruses, their preparation and their use in gene therapy
ZA952244A ZA952244B (en) 1994-03-18 1995-03-17 Recombinant viruses their preparation and their use in gene therapy
NO963559A NO963559L (no) 1994-03-18 1996-08-26 Rekombinante adenoviruser som koder for hjerne-avledet naurotrofisk faktor (BDNF)
FI963674A FI963674A0 (fi) 1994-03-18 1996-09-17 Yhdistelmä-DNA-adenoviruksia, jotka koodittavat aivoperäistä neurotrofista tekijää (BDNF)
US10/742,920 US20040224409A1 (en) 1992-09-25 2003-12-23 Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9403191A FR2717496B1 (fr) 1994-03-18 1994-03-18 Virus recombinants, préparation et utilisation en thérapie génique.

Publications (2)

Publication Number Publication Date
FR2717496A1 FR2717496A1 (fr) 1995-09-22
FR2717496B1 true FR2717496B1 (fr) 1996-04-12

Family

ID=9461190

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9403191A Expired - Fee Related FR2717496B1 (fr) 1992-09-25 1994-03-18 Virus recombinants, préparation et utilisation en thérapie génique.

Country Status (12)

Country Link
EP (1) EP0750676A1 (ja)
JP (1) JPH09510358A (ja)
KR (1) KR970701784A (ja)
AU (1) AU703793B2 (ja)
CA (1) CA2184200A1 (ja)
FI (1) FI963674A0 (ja)
FR (1) FR2717496B1 (ja)
IL (1) IL112992A0 (ja)
MX (1) MX9603490A (ja)
NO (1) NO963559L (ja)
WO (1) WO1995025804A1 (ja)
ZA (1) ZA952244B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830857A (en) * 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy
FR2753379B1 (fr) 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
DE60137414D1 (de) * 2000-05-05 2009-03-05 Univ City Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese
WO2019162942A1 (en) * 2018-02-20 2019-08-29 Carmel Haifa University Economic Corporation Ltd. Compositions and methods for delivery and expression of small inhibitory peptides and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113083A1 (en) * 1991-07-10 1993-01-21 Vivien Wong Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules
US5733871A (en) * 1991-11-08 1998-03-31 The General Hospital Corporation Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU4995193A (en) * 1992-08-04 1994-03-03 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
DE69334238D1 (de) * 1992-09-25 2008-09-25 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.

Also Published As

Publication number Publication date
CA2184200A1 (fr) 1995-09-28
FI963674A (fi) 1996-09-17
IL112992A0 (en) 1995-06-29
FR2717496A1 (fr) 1995-09-22
MX9603490A (es) 1997-03-29
AU1896295A (en) 1995-10-09
ZA952244B (en) 1996-01-16
NO963559L (no) 1996-08-26
KR970701784A (ko) 1997-04-12
FI963674A0 (fi) 1996-09-17
AU703793B2 (en) 1999-04-01
EP0750676A1 (fr) 1997-01-02
WO1995025804A1 (fr) 1995-09-28
JPH09510358A (ja) 1997-10-21

Similar Documents

Publication Publication Date Title
FR2712603B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2716893B1 (fr) Virus recombinants, leur préparation et leur utilisation thérapeutique.
FR2718150B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2712602B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
DK0595436T3 (da) Porcint respirations- og reproduktionssygdomsvirus, vacciner og viralt dna
FR2725726B1 (fr) Vecteurs viraux et utilisation en therapie genique
NO950939L (no) Defektive adenovirusvektorer og deres anvendelse i gene-terapien
AU3824595A (en) Recombinant negative strand RNA virus expression systems and vaccines
FR2704234B1 (fr) Virus recombinants, preparation et utilisation en therapie genique.
AU2328397A (en) Recombinant live feline immunodeficiency virus and proviral dna vaccines
AU1927797A (en) Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
ZA964679B (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
OA09664A (en) Virus/herbicide-resistance genes, processes for the preparation thereof and the use thereof
FR2717495B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
NO974179L (no) Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi
CA2278808A1 (en) Methods for cultivating cells and propagating viruses
FI971275A0 (fi) Inaktivoidun IVa2-geenin käsittävät epätäydelliset yhdistelmä-DNA-tekniset adenovirukset
FR2717496B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2717823B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2717497B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2725213B1 (fr) Vecteurs viraux et utilisation en therapie genique
NO902248L (no) Renininhiberende peptider, deres fremstilling og anvendelse i legemidler.
FR2726575B1 (fr) Virus recombinants, preparation et utilisation en therapie genique
PL346859A1 (en) Recombinant celo virus and celo virus dna
FR2718749B1 (fr) Vecteurs viraux et utilisation en thérapie génique.

Legal Events

Date Code Title Description
CD Change of name or company name
ST Notification of lapse

Effective date: 20111130